Marvel Biosciences Corp.
Loading stock data...
Stock Performance
Price History
-
Drag to select time range
-
Market Data
Market Cap
8.4M
P/E Ratio
-
52-Week High
-
52-Week Low
-
Avg Volume
-
Beta
-
Forward P/E
-
Dividend Yield
-
EV/Revenue
-
Price/Book
-
Business Overview
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.
Healthcare
Biotechnology
TSXV
Key Financial Metrics
-
Revenue
-2.2M
Net Income
C$-0.05
EPS (Diluted)
-1.2M
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-
Net Profit Margin
-
EBITDA
-1.9M
Returns & Efficiency
Return on Assets (ROA)
-676.9%
Return on Equity (ROE)
-
Dividend Yield
-
Payout Ratio
-
Financial Health
Total Assets
326,715
Total Debt
2.3M
Debt to Equity
-
Current Ratio
0.08
Company Info
| Industry | Biotechnology |
| HQ | Calgary, Canada |
| Fiscal Year End | 1753920000 |
| Currency | CAD |
| Website | marvelbiotechnology.com |
Peers
Bausch + Lomb Corporation
BLCO.TO
7.9B
P/E: --
Bausch Health Companies Inc.
BHC.TO
2.5B
P/E: 12.0
Extendicare Inc.
EXE.TO
2.5B
P/E: 23.7
Sienna Senior Living Inc.
SIA.TO
2.2B
P/E: 53.2
Cronos Group Inc.
CRON.TO
1.4B
P/E: 24.1
Tilray Brands, Inc.
TLRY.TO
1.2B
P/E: --
WELL Health Technologies Corp.
WELL.TO
1.1B
P/E: --
Knight Therapeutics Inc.
GUD.TO
631.8M
P/E: --
Insider Activity
Sentiment
Bullish
Shares Bought
6,735,309
Shares Sold
0
Total Transactions
31
SEDAR+ Filings
View All Filings7
Annual Reports
16
Quarterly Reports
23
MD&A
59
News Releases
6
Material Changes
2
Prospectuses
8
Governance
48
Certifications
49
Other
●
2019-01-25
●
2018-12-21
Interactive Charts
Company Profile
General Information
| Company Name | Marvel Biosciences Corp. |
| Ticker | MRVL.V |
| Exchange | TSXV |
| Sector | Healthcare |
| Industry | Biotechnology |
| Headquarters | Calgary, Canada |
| Fiscal Year End | 1753920000 |
| Currency | CAD |
| Website | marvelbiotechnology.com |
Financial Summary
| Market Cap | 8.4M |
| Revenue | N/A |
| Net Income | -2.2M |
| P/E Ratio | N/A |
| EPS (Diluted) | C$-0.05 |
| Net Margin | N/A |
| ROE | N/A |
| Dividend Yield | N/A |
Business Description
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.